Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on in-hospital mortality in COVID-19 patients: a systematic review and meta-analysis

Xinzhe James Cai1,*, MBBS, MRCP, Julian Cheong Kiat Tay1,*, MBBS, MRCP, Swee Leng Kui1, MBChB, MRCP, Aung Soe Tin2, MBBS, MMed, Vern Hsen Tan1,3, MBBS, MRCP

1Department of Cardiology, 2Health Services Research, Changi General Hospital, 3Cardiovascular Sciences Academic Clinical Programme, Singhealth Duke-NUS, Singapore

*These authors contributed equally as first authors in this work.

Correspondence: Dr Tan Vern Hsen, Senior Consultant, Department of Cardiology, Changi General Hospital, 2 Simei Street 3, Singapore 529889. tan.vern.hsen@singhealth.com.sg

Singapore Med J 2020, 1–16
https://doi.org/10.11622/smedj.2020159
Published ahead of print: 30 November 2020

Online version can be found at
http://www.smj.org.sg/online-first
**ABSTRACT**

**Introduction:** There are concerns that angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) may worsen outcomes in patients with coronavirus disease 2019 (COVID-19). This systemic review and meta-analysis aimed to study in-hospital mortality in COVID-19 patients who were on ACEI/ARB as compared to those not on ACEI/ARB.

**Methods:** We search PubMed, EMBASE, clinicaltrials.gov and Google Scholar between 1 January 2020 and 30 May 2020 to identify all studies that evaluated the use of ACEI/ARB and reported the in-hospital mortality outcomes in COVID-19 patients. Nine non-randomised studies were eligible for inclusion in the analysis. The primary outcome studied was in-hospital mortality of COVID-19 patients who were on ACEI/ARB compared with those not on ACEI/ARB.

**Results:** Of the 8,313 patients in the nine studies, 7,622 (91.7%) were from studies with all-comers, while 691 (8.3%) were from studies with only hypertensive patients. 577 (14.6%) in-hospital deaths were observed out of a total of 3,949 patients with an outcome in the nine studies. Overall, there was no significant difference in in-hospital mortality between patients on ACEI/ARB and those not on ACEI/ARB (odds radio [OR] 1.06, 95% confidence interval [CI] 0.75–1.50; p = 0.73). Further sensitivity analysis in the hypertensive group and all-comers group showed similar results (OR 0.88, 95% CI 0.58–1.32; p = 0.53 and OR 1.85, 95% CI 1.00–3.43; p = 0.05, respectively).

**Conclusion:** This study found that ACEI/ARB has no significant impact on in-hospital mortality in COVID-19 patients and can be used safely in patients with indications.

**Keywords:** angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, coronavirus disease 2019, hypertension, mortality
INTRODUCTION

Coronavirus disease 2019 (COVID-19) is a worldwide pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first reported in Wuhan, Hubei, China in December 2019.\(^{(1)}\) It has since caused serious socioeconomic burden and put an unprecedented strain on healthcare systems worldwide. Hypertension and cardiovascular disease are common morbidities among patients with COVID-19, and they have also been shown to be associated with higher mortality and worse outcomes.\(^{(2-5)}\)

Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are renin-angiotensin-aldosterone system (RAAS) inhibitors that are commonly prescribed for hypertension, cardiac disease and renal disease. The use of RAAS inhibitors has been reported to increase the expression of angiotensin-converting enzyme 2 (ACE2) in animal studies.\(^{(6)}\) As ACE2 serves as the receptor for SARS-CoV-2 for host cell entry, there have been concerns that a higher ACE2 expression may lead to worse outcomes in patients with COVID-19 who are taking ACEI/ARB.\(^{(7-9)}\) Multiple major international societies have since published position statements regarding the use of ACEI/ARB in patients with COVID-19, recommending the continuation of these medications for patients who have clinical indications such as heart failure and hypertension.\(^{(10,11)}\)

The significance of ACEI/ARB on the clinical outcomes of patients with COVID-19 has mostly been studied in small observational studies of COVID-19 patients. This systematic review and meta-analysis sought to quantify the effect of ACEI/ARB on the risks of in-hospital mortality in COVID-19 patients.
METHODS

This meta-analysis was performed in adherence to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and MOOSE (Meta-analysis of Observational Studies in Epidemiology) checklist on the quality of reporting of meta-analyses.\textsuperscript{(12)} The study was approved by the SingHealth Centralised Institutional Review Board (2020/2452).

Two independent reviewers (VHT and XJC) searched PubMed, EMBASE, clinicaltrials.gov and Google Scholar for relevant articles on ACEI/ARB-related outcomes in COVID-19 patients. The following search terms were used in the literature review: ‘COVID-19’, ‘coronavirus disease 2019’, ‘angiotensin-converting enzyme inhibitors’, ‘ACE inhibitors’, ‘ACEI’, ‘angiotensin receptor blockers’, ‘ARB’, ‘renin angiotensin aldosterone system inhibitors’ and ‘renin angiotensin aldosterone system’. They also searched the reference lists of all published studies and biographies of review articles to identify additional articles. No language or publication status restrictions were applied. The search was conducted from 1 January 2020 (as COVID-19 was first reported in late December 2019) to 30 May 2020. Only studies in which in-hospital mortality data was reported or available were included. The corresponding authors of the studies were also contacted to provide their unpublished data. Any disagreements were resolved in a panel discussion consisting of three reviewers (VHT, JCKT and XJC).

Study selection involved the screening of titles and abstracts, followed by full-text evaluation of the eligible studies. The inclusion criteria were: (a) study population comprising all patients with COVID-19 with or without ACEI/ARB use; and (b) reported in-hospital mortality outcomes. The primary outcome measure was in-hospital mortality. Data was independently extracted by two of the study investigators (VHT and JCKT) using a standardised protocol and reporting form (Appendix). Any disagreements were resolved by arbitration, and consensus was
achieved after discussion. The following data was collected: study characteristics (study name, authors, sample size, study design and follow-up duration); study sample characteristics (mean age, gender, major comorbidities and prescription of ACEI/ARB); and main outcomes.

Data was pooled and analysed using RevMan Version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014). A random effect model was used for summarising effects. The effect size is presented as odds ratio (OR) with 95% confidence interval (CI). All statistical tests were two-sided and used a significance level of p < 0.05. Statistical heterogeneity was evaluated using the Higgins and Thompson I² statistic. The I² is the proportion of total variation observed among the studies that is attributable to differences between studies rather than sampling error (chance), with I² values corresponding to the following levels of heterogeneity: low (< 25%); moderate (25%–75%); and high (> 75%).(13) Reasons for the heterogeneity in the study results were further explored using subgroup analyses, which were performed according to the presence of hypertension as a comorbid. We also performed a sensitivity analysis to investigate the association of each individual study with the overall meta-analysis results.

RESULTS

Our database search resulted in 560 unique studies. Of those, 528 were deemed irrelevant based on title and abstract screenings. The full text of 32 studies were assessed for eligibility, of which nine met the final inclusion criteria and were included in the main analysis of this study (Fig. 1).(14-22) The nine studies comprised observational case series, cohort studies and case-control studies. There were no randomised controlled trials.
The characteristics of the patients in these nine studies are shown in Table I. A total of 8,313 patients were included in this study, of whom 7,622 (91.7%) were in the ‘all-comers’ group (included patients with and without hypertension). 691 (8.3%) patients belonged to the ‘hypertension-only’ group. In the all-comers group, there were slightly fewer female (42.4%) patients than male patients, and a significant proportion of patients had hypertension (49.4%), diabetes mellitus (28.4%), coronary artery disease (10.2%) or respiratory disease (13.6%). The hypertension-only group had an almost equal proportion of female (47.9%) to male patients, with
a higher prevalence of diabetes mellitus (30.0%) and coronary artery disease (15.8%) but a lower prevalence of respiratory disease (4.5%), as compared to the all-comers group.

In terms the use of ACEI/ARB, the hypertension-only group had, unsurprisingly, a higher proportion of ACEI/ARB use compared to the all-comers group (34.5% vs 5.7%). Out of the 3,949 patients with outcomes in the combined nine studies, 577 (14.6%) in-hospital deaths were observed, with 172 (4.4%) deaths in the ACEI/ARB group and 405 (10.2%) deaths in the non-ACEI/ARB group. There was no significant increase in in-hospital mortality in the ACEI/ARB group versus the non-ACEI/ARB group (OR 1.06, 95% CI 0.75–1.50, p = 0.73; Fig. 2). There was no significant heterogeneity observed in the analysis ($I^2 = 25\%$, $p = 0.22$). Cardiovascular and non-cardiovascular deaths were not reported in any of the studies, thus preventing analysis of the effect of ACEI/ARB on cardiovascular death.

![Table](https://via.placeholder.com/150)

**Fig. 2** Diagram shows the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (ACEI/ARB) vs. non-ACEI/ARB use in all COVID-19 patients and the risk of in-hospital mortality (events) for the nine included studies. (14-22)

There were seven studies with in-hospital mortality outcomes that focused on hypertension-only patients. (15,16,18-22) One study by Richardson et al (19) presented the clinical characteristics of all-comers but only reported in-hospital mortality for hypertensive patients. In this subset of 2,057 hypertension-only patients, there were 492 (23.9%) in-hospital deaths – 157 (7.6%) deaths in the ACEI/ARB group and 335 (16.3%) deaths in the non-ACEI/ARB group.
Similarly, the use of ACEI/ARB in this study was not associated with any significant difference in in-hospital mortality in hypertension-only patients (OR 0.88, 95% CI 0.58–1.32, p = 0.53; Fig. 3). There was no heterogeneity observed in the seven studies ($I^2 = 25\%$; p = 0.24).

![Fig. 3 Diagram shows the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (ACEI/ARB) vs. non-ACEI/ARB use in hypertensive COVID-19 patients and the risk of in-hospital mortality (events) for the seven studies that reported in-hospital mortality in both subgroups.](image1)

There were two studies that reported in-hospital mortality outcomes in all-comers. In the subset of all-comers, there were 85 in-hospital deaths (4.5%) reported out of 1,892 patients across the two studies – 15 (0.8%) deaths in the ACEI/ARB group and 70 (3.7%) death in the non-ACEI/ARB group. The use of ACEI/ARB was not associated with any significant difference in in-hospital mortality in all-comers (OR 1.85, 95% CI 1.00–3.43, p = 0.05; Fig. 4). There was no heterogeneity observed in the two studies ($I^2 = 0\%$; p = 0.72).

![Fig. 4 Diagram shows the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (ACEI/ARB) vs. non-ACEI/ARB use in COVID-19 all-comer patients and the risk of in-hospital mortality (events) for two studies that reported in-hospital mortality in both subgroups.](image2)
DISCUSSION

This analysis demonstrated that (a) the use of ACEI/ARB does not result in a significant increase in in-hospital mortality outcomes in patients with COVID-19 and (b) there is a higher prevalence of comorbidities, particularly hypertension, in COVID-19 patients.

Hypertension is one of the top causes of premature death globally, with an estimated prevalence of 31.1% among the worldwide adult population > 20 years old in 2010.\textsuperscript{(23)} Hypertension has also been frequently reported as a major comorbidity in COVID-19 patients, and this is further supported by our pooled analysis of 8,313 patients with a prevalence of 49.4%.\textsuperscript{(1–5)}

There is ongoing debate regarding the effect of ACEI/ARB on the outcomes of patients with COVID-19 and whether these medications should be discontinued. This underlying concern stems from both previous and recent studies that have demonstrated that ACE2 is the cellular entry point and mediator of infection and transmission not only in severe acute respiratory syndrome coronavirus (SARS-CoV), the culprit coronavirus in the 2003 SARS outbreak, but also in SARS-CoV-2.\textsuperscript{(24–26)} This is further supported by studies that showed a 79% similarity in the genomic sequence of SARS-CoV-2 and SARS-CoV.\textsuperscript{(27)}

However, this concern regarding the use of ACEI/ARB in patients with COVID-19 has not been proven in clinical studies. At the same time, it has been postulated that ACEI/ARB may have a beneficial effect on patients with COVID-19, with evidence of downregulation of ACE2 expression by SARS-CoV-2.\textsuperscript{(28)} It has been shown that RAAS activation plays an important role in acute respiratory distress syndrome (ARDS).\textsuperscript{(29)} Kuba et al found that downregulation of ACE2 by SARS-CoV, the culprit coronavirus for the 2003 SARS outbreak, worsens lung injury in mice models.\textsuperscript{(30)} This suggested that modulation of the RAAS system could improve outcomes in ARDS. Moreover, stopping essential medications that are guideline-recommended treatment for
hypertension, heart failure and kidney failure, among other indications, can have deleterious effects on patients’ blood pressure and haemodynamics.

Our findings that ACEI/ARB have no significant impact on in-hospital mortality in COVID-19 patients are in keeping with the positional statements of major international professional societies, such as the American College of Cardiology, American Heart Association, Heart Failure Society of America and European Society of Cardiology.(10,11)

The present study was not without limitations. Individual patient data was not available and thus our ability to look at specific patient characteristics, such as clinical indication for ACEI/ARB, age and other comorbidities of the patient population, was limited. In addition, the short period of study and availability of many studies posed a degree of limitation in terms of quality assessment of the included studies. However, given the urgency and global scale of the pandemic, it is crucial to include all available data to provide a more complete assessment of the effect of ACE/ARB on COVID-19 mortality. The degree of publication bias was also likely to be limited given the call for openness and transparency of all COVID-19-related information.

Another important limitation is that most of the studies did not describe in detail the initiation, continuation and cessation of ACEI/ARB during hospitalisation, with the exception of Richardson et al’s study.(19) The definition of ACEI/ARB exposure was also not clearly defined and thus, it was unclear whether these medications were prescribed on admission or throughout the entire admission; this is important, as it may potentially compound the effect of the study. Richardson et al reported that among patients taking ACEI/ARB at home, 48.1% and 50.1% continued taking an ACEI and ARB, respectively, while in hospital. Of the 953 patients with hypertension who were not prescribed an ACEI or ARB at home, 49 and 58 patients started ACEI and ARB, respectively, during hospitalisation.(19)
As COVID-19 is an emerging novel viral infection, the number of observational studies is limited and the study size is generally small. There were seven small studies contributing fewer than 500 patients each. Two large studies made up a total of 7,435 (89.4%) out of the total patient population of 8,313 patients analysed.\(^{17,19}\) Although we cannot rule out the possibility of selection bias, it is unlikely to substantially influence the outcome, as our meta-analysis included studies from multiple countries (China, Italy, United Kingdom and United States of America) with varying patient populations across the world. This, in fact, helps to strengthen the international societies’ position statements and reassure physicians managing patients with COVID-19 around the world.

The studies included in this meta-analysis are all either case-control or case-series observational studies, which have weaknesses that are inherent to observational data. To our knowledge, there are ongoing randomised clinical trials studying the use of ACEI/ARB in COVID-19, including one on Losartan, which will further clarify the effect of ACEI/ARB in COVID-19 mortality outcomes.\(^{31}\)

In conclusion, this meta-analysis shows that ACEI/ARB has no significant impact on in-hospital mortality in patients with COVID-19. This result concurs with the recommendations made by major international professional societies to not discontinue ACEI/ARB in patients with relevant indications. This result will help to guide physicians caring for patients with COVID-19 on these medications.

**REFERENCES**

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497-506.

2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019
novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323:1061-9.

3. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708-20.

4. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180:934-43.

5. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020; 323:1488-94.

6. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:2605-10.

7. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020; 94:e00127-20.

8. Hofmann H, Geier M, Marzi A, et al. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun 2004; 319:1216-21.

9. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020; 8:e21.

10. European Society of Cardiology. Position statement of the ESC Council on hypertension on ACE-inhibitors and angiotensin receptor blockers. Available at: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed May 7,
11. American College of Cardiology. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Available at: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. Accessed May 7, 2020.

12. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.

13. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Chichester, UK: John Wiley & Sons Ltd, 2008.

14. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5:811-8.

15. Huang Z, Cao J, Yao Y, et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. Ann Transl Med 2020; 8:430.

16. Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol 2020; 5:825-30.

17. Mehta N, Kalra A, Nowacki AS, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5:1020-6.

18. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020; 9:757-
60.

19. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323:2052-9.

20. Yang G, Tan Z, Zhou L, et al. Effects of angiotensin II receptor blockers and ACE (angiotensin-covering enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertension 2020; 76:51-8.

21. Zeng Z, Sha T, Zhang Y, et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: a single-center retrospective observational study. medRxiv 2020 April 11. https://doi.org/10.1101/2020.04.06.20054825. [Preprint]

22. Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. Clin Exp Hypertens 2020; 42:656-60.

23. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016; 134:441-50.

24. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426:450-4.

25. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci 2004; 25:291-4.

26. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579:270-3.
27. Song Y, Liu P, Shi XL, et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut 2020; 69:1143-4.

28. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020; 63:364-74.

29. Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Crit Care 2017; 21:305.

30. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11:875-9.

31. Losartan for patients with COVID-19 requiring hospitalization. In: ClinicalTrials.gov [online]. Available at: https://clinicaltrials.gov/ct2/show/NCT04312009. Accessed May 30, 2020.
Table I. Characteristics of all patients included in the analysis.

| Study            | No.  | Study type | Centre | Population* | Age† (yr) | LOS† (day) | %                      |
|------------------|------|------------|--------|-------------|-----------|------------|------------------------|
|                  |      |            |        |             |           |            | Female  | HTN  | DM  | CAD  | CCF  | CKD  | CVA  | RD  | ACEI | ARB | ACEI/ARB |
| Guo et al(14)    | 187  | Case series| Single | All-comer   | 58.5 ± 14.6 | 16.6 ± 8.1 | 51.3     | 32.6 | 15.0 | 11.2 | 4.3  | 3.2  | NA   | 2.1 | NA  | NA  | 10.2  |
| Huang et al(15)  | 50   | Case series| Single | HTN        | 61.7       | 43.5       | 46.0     | 100.0 | 8.0  | 2.0  | NA   | NA   | NA   | 0.0  | NA  | NA  | 40.0  |
| Li et al(16)     | 362  | Case series| Single | HTN        | 66.0 (59.0–73.0) | 19.0 (12.0–27.0) | 47.8     | 100.0 | 35.1 | 17.1 | 2.8  | 9.7  | 18.8 | 5.0  | 9.7 | 22.9 | 32.6  |
| Mehta et al(17)  | 1,735| Case series| Single | All-comer  | 63.0       | NA         | 50.5     | 39.3 | 19.1 | 9.3  | 8.4  | NA   | NA   | 6.6  | 6.7 | 5.6  | 12.2  |
| Meng et al(18)   | 42   | Case series| Single | HTN        | 66.0 (59.0–73.0) | 19.0 (12.0–27.0) | 47.8     | 100.0 | 14.3 | 0.0  | 0.0  | 0.0  | 0.0  | 4.8  | 35.7| 40.5 |
| Richardson et al(19)† | 5,700| Case series| Multi | All-comer  | 63.0 (52.0–75.0) | 4.5 (2.4–8.1) | 39.7     | 53.1 | 31.7 | 10.4 | 6.5  | 8.0  | NA   | 16.1 | 7.0 | 10.2 | 17.1 |
| Yang et al(20)   | 126  | Case-control| Single | HTN        | 66.0 (61.0–73.0) | NA        | 50.8     | 100.0 | 30.2 | 18.3 | NA   | 2.4  | 7.9  | 4.8  | NA  | NA  | 34.1  |
| Zeng et al(21)   | 75   | Observational| Single | HTN        | 67.0±11.0 | 22.0 (15.0–26.0) | 45.3     | 100.0 | 30.7 | 21.3 | NA   | 5.3  | 14.7 | 9.3  | NA  | NA  | 37.3  |
| Zhou et al(22)   | 36   | Case series | Single | HTN        | 64.8±10.1 | 11.1±5.6 | 47.2     | 100.0 | 25.0 | 19.4 | NA   | NA   | NA   | NA   | NA  | NA  | 41.7  |

*All-comer refers to studies that included data on patients with or without hypertension while, HTN refers to studies that included only data on hypertensive patients. †Data presented as either mean, mean ± standard deviation or median (interquartile range). ‡This study included baseline characteristics of all-comer patients and outcome data for hypertension-only patients; for sensitivity analysis, this study was included in the hypertension-only subgroup.

ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blockers; CAD: coronary artery disease; CCF: congestive cardiac failure; CKD: chronic kidney disease; CVA: cerebrovascular accidents; DM: diabetes mellitus; HTN: hypertension; LOS: length of hospital stay; NA: not available; RD: respiratory disease
## APPENDIX

### Standardised Protocol and Reporting Form

| COVID-19 and ACEI/ARB meta-analysis |
|-------------------------------------|
| **STUDY SUMMARY**                  |
| 1. Lead author                     |
| 2. Journal/Year of publication     |
| 3. Study Type                      |
| □ Case-series                      |
| □ Case-control                     |
| □ Observational                    |
| □ Cohort                           |
| □ Randomised control trial         |
| 4. Population                      |
| □ All-comers (Both hypertensive and non-hypertensive) |
| □ Hypertensive only                |
| **BASELINE DEMOGRAPHICS**          |
| 5. Mean age (SD), years            |
| 6. Median age (IQR), years         |
| 7. Mean hospitalisation (SD), days |
| 8. Median hospitalisation (IQR), days |
| 9. Total patients (%), n           |
| 10. Females (%), n                 |
| **CO-MORBIDITIES**                 |
| 11. Hypertension (%), n            |
| 12. Diabetes Mellitus (%), n       |
| 13. Dyslipidemia (%), n            |
| 14. CAD (%), n                     |
| 15. CCF (%), n                     |
| 16. CKD (%), n                     |
| 17. Respiratory disease (%), n     |
| 18. CVA (%), n                     |
| **ACEI/ARB use**                   |
| 19. ACEI (%), n                    |
| 20. ARB (%), n                     |
| 21. ACEI/ARB (%), n                |
| 22. Without ACEI/ARB (%), n        |
| **OUTCOMES**                       |
| 23. Number of ACEI/ARB dead (%), n |
| 24. Number of ACEI/ARB alive (%)   |
| 25. Number of those without ACEI/ARB dead (%), n |
| 26. Number of those without ACEI/ARB alive (%) |
| 27. Follow-up duration, days       |

ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blockers; CAD: coronary artery disease; CCF: congestive cardiac failure; CKD: chronic kidney disease; COVID-19: coronavirus disease 2019; CVA: cerebrovascular accidents; IQR: interquartile range; SD: standard deviation